Cardiff Oncology (CRDF) Prices 6.5M Share Common Offering at $13.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
After-Hours Stock Movers 9/29: (CTIC) (JFIN) (CMTL) Higher; (FCEL) (PRGS) (MU) Lower (more...)
September 29, 2020 5:54 PM EDTToday's After-Hours Stock Movers
CTI BioPharma Corp. (Nasdaq: CTIC) 167% HIGHER; announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration, the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count less than 50 x 109/L). The NDA will be based on the available data from the Company's completed Phase 3 PERSIST-1 and PERSIST-2 trials and the Phase 2 PAC203 dose-ranging trial. The FDA has agreed to a... More
Cardiff Oncology (CRDF) Announces Proposed Common Share Offering
September 29, 2020 4:04 PM EDTCardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, announced today that it has commenced an underwritten public... More
